Arcus Biosciences (RCUS) Other Accumulated Expenses (2017 - 2026)

Arcus Biosciences' Other Accumulated Expenses history runs 10 years deep, the most recent figure standing at $136.0 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 38.78% year-over-year to $136.0 million in Q1 2026; TTM through Mar 2026 was $136.0 million, a 38.78% increase from a year earlier, with the FY2025 full-year figure at $154.0 million, up 25.2% from the prior year.
• Other Accumulated Expenses fell to $136.0 million in Q1 2026 per RCUS's latest filing, from $154.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $154.0 million in Q4 2025 and bottomed at $1.5 million in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $76.0 million (2022), against an average of $78.5 million.
• Across the five-year window, Other Accumulated Expenses slumped 94.92% in 2022 and surged 3791.05% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $76.0 million in 2022, then changed by 0.0% to $76.0 million in 2023, then surged by 61.84% to $123.0 million in 2024, then gained by 25.2% to $154.0 million in 2025, then decreased by 11.69% to $136.0 million in 2026.
• Per Business Quant, the three latest RCUS Other Accumulated Expenses figures stand at $136.0 million (Q1 2026), $154.0 million (Q4 2025), and $141.0 million (Q3 2025).